Leo tames eczema in phase 2b, reporting primary endpoint hit for ex-argenx asset
Leo Pharma has shared phase 2b data on its eczema prospect temtokibart, reporting that the top three doses of the IL-22RA1 blocker beat placebo on the primary endpoint.
Leo Pharma has shared phase 2b data on its eczema prospect temtokibart, reporting that the top three doses of the IL-22RA1 blocker beat placebo on the primary endpoint.
